Drug Pipeline Database & Screener

Over 1500 drug entries from over 400 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 


Visit the FDA Calendar for  latest Biotech Stock Catalyst dates (PDUFA dates and clinical data readouts).

Alternatively, the BioPharmCatalyst Biotech Stocks page provides data on daily price and volume movers and information on individual companies.


Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-35 minutes.


Showing 441 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
AAAP Advanced Accelerator Applications S.A.
$73.68
+1.04  1.43%
$3.3 billion
44.2 million
0.10
08/28/2017
Tap to view 6 drugs
Drug Indication Stage News
Annexin V-128 Early Breast Cancer Phase 2 Phase 2 initiated September 2016
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Apoptosis Necrosis Phase 2 Phase 2 initiated September 2016
Lutathera Inoperable progressive midgut NETs PDUFA CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1, 2016.
Somakit-TOC Neuroendocrine cancers – Positive opinion by EMA released in October 2016.
ABBV AbbVie Inc.
$95.69
-0.79  -0.82%
$152.5 billion
1.6 billion
1.91
10/10/2017
Tap to view 29 drugs
Drug Indication Stage News
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
ABT-494 Crohn’s Disease Phase 2b Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494 Atopic Dermatitis Phase 2b Phase 2b data released September 7, 2017 - primary endpoint met.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
ABT-494 (upadacitinib) - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Elagolix Uterine Fibroids Phase 3 Phase 3 initiated in January 2016. Data due late 2017.
Elagolix Endometriosis NDA Filing First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica - PHOENIX First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial ongoing.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis Phase 3 Phase 3 data due by the end of 2017.
Risankizumab Psoriatic Arthritis Phase 2b Phase 2b data due 2017.
Rova-T First-line small cell lung cancer (SCLC) maintenance Phase 3 Phase 3 trial to commence 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data due 2017.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial to commence 2017.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial to commence 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Phase 3 Phase 3 data released September 18, 2017 - PFS primary endpoint met.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016. Data due 2019.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
ABEO Abeona Therapeutics Inc.
$19.15
+1.40  7.89%
$783.5 million
40.9 million
3.90
10/11/2017
Tap to view 3 drugs
Drug Indication Stage News
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 commencement of enrollment in pivotal trial expansion announced October 11, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Noted July 18, 2017 that Phase 3 trial will commence in early 2018.
ABIO ARCA biopharma Inc.
$1.30
-0.01  -0.38%
$18.7 million
14.4 million
3.00
08/16/2017
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b completion of enrollment announced August 16, 2017 - top-line data due late 1Q 2018.
ABUS Arbutus Biopharma Corporation
$6.53
+0.12  1.95%
$362.3 million
55.5 million
0.52
09/25/2017
Tap to view 4 drugs
Drug Indication Stage News
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 4Q 2017.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017 - entitled to low to mid-single-digit royalty payments on sales of patisiran by Alnylam.
TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
ACAD ACADIA Pharmaceuticals Inc.
$36.32
+0.49  1.37%
$4.4 billion
122.4 million
5.09
10/04/2017
Tap to view 5 drugs
Drug Indication Stage News
Pimavanserin Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016.
Pimavanserin Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial initiation announced October 4, 2017.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
ACER Acer Therapeutics Inc.
$17.81
-0.00  -0.01%
$13.2 million
739.4 thousand
1.30
09/25/2017
Tap to view 2 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome Phase 3 NDA filing 1H 2018.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACHN Achillion Pharmaceuticals Inc.
$4.17
+0.01  0.24%
$570.3 million
136.8 million
4.50
09/11/2017
Tap to view 4 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) – Phase 2 trial to be initiated 2H 2017.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
ACHV Achieve Life Sciences Inc.
$1.92
+0.07  3.58%
$21.6 million
11.3 million
1.70
08/14/2017
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 3 Phase 3 trial to be initiated 1H 2018.
ACIU AC Immune SA
$11.89
+0.14  1.19%
$676.8 million
56.9 million
8.51
09/12/2017
Tap to view 4 drugs
Drug Indication Stage News
ACI-24 (anti-Abeta vaccine) Alzheimer’s disease Phase 1/2 Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017.
ACI-35 (anti-tau vaccine) Alzheimer’s disease Phase 1b Phase 2 trial to commence 2017.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Second Phase 3 trial initiation announced February 28, 2017.
ACOR Acorda Therapeutics Inc.
$27.15
+0.45  1.69%
$1.3 billion
46.7 million
8.87
09/27/2017
Tap to view 5 drugs
Drug Indication Stage News
Ampyra Improve walking in patients with multiple sclerosis – Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-427 Migraine Phase 2 Phase 2 to be initiated by the end of 2017.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301) OFF episodes of Parkinson’s disease (PD) NDA Filing Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017. Noted September 27, 2017 that it intends to refile NDA with need to hold a Type A meeting.
Tozadenant Parkinson’s disease (PD) Phase 3 Phase 3 data due 1Q 2018.
ACRS Aclaris Therapeutics Inc.
$26.12
-0.52  -1.93%
$698.2 million
26.7 million
11.50
08/08/2017
Tap to view 4 drugs
Drug Indication Stage News
A-101 Seborrheic keratosis (SK) PDUFA PDUFA date is December 24, 2017
A-101 Common warts (verruca vulgaris) Phase 2b Phase 2 data released August 2016. Phase 2b trial initiation announced June 29, 2017.
ATI-50001 Alopecia totalis and alopecia universalis Phase 2 Phase 2 trial to be initiated 2H 2017.
ATI-50002 Patchy alopecia areata Phase 2 Phase 2 trial to be initiated 2H 2017.
ACRX AcelRx Pharmaceuticals Inc.
$1.93
+0.17  10.00%
$87.4 million
45.4 million
3.50
10/12/2017
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure CRL CRL issued October 12, 2017.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Phase 3 trial initiated September 2016. Data released August 1, 2017 with NDA to be refiled by the end of 2017.
ACST Acasti Pharma Inc.
$1.32
+0.02  1.54%
$19.5 million
14.7 million
0.39
08/14/2017
Tap to view 1 drug
Drug Indication Stage News
CaPre Hypertriglyceridemia Phase 3 Phase 3 to be initiated 2H 2017.
ADAP Adaptimmune Therapeutics plc
$7.18
+0.08  1.13%
$671.5 million
93.5 million
1.23
11/21/2016
Tap to view 5 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 3 Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Further trials planned for 2H 2016
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 3 Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy Myeloma Phase 1/2 Further trials planned for 1H 2017.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
ADHD Alcobra Ltd.
$1.58
+0.07  4.64%
$43.5 million
27.6 million
3.80
02/22/2017
Tap to view 3 drugs
Drug Indication Stage News
MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2 Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2 Phase 2 trial did not meet endpoints - June 2015.
ADMA ADMA Biologics Inc
$3.04
+0.18  6.29%
$52.3 million
17.2 million
1.18
06/27/2017
Tap to view 1 drug
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases CRL CRL issued July 29 2016. Third-party manufacturing isses cited. Noted June 27, 2017 its intention to refile BLA in mid-2018.
ADMP Adamis Pharmaceuticals Corporation
$5.45
+0.20  3.81%
$170.9 million
31.4 million
4.18
10/10/2017
Tap to view 2 drugs
Drug Indication Stage News
APC-1000 Asthma/COPD Phase 2 Phase 3 planned.
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
ADMS Adamas Pharmaceuticals Inc.
$19.26
-0.16  -0.82%
$433.6 million
22.5 million
7.55
09/07/2017
Tap to view 4 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Phase 1b top-line data released September 7, 2017.
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADRO Aduro Biotech Inc.
$9.25
+0.03  0.27%
$690.2 million
74.6 million
10.17
10/04/2017
Tap to view 6 drugs
Drug Indication Stage News
ADU-S100 Solid tumors or lymphomas Phase 1b Phase 1b initiation of dosing announced September 26, 2017.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with KEYTRUDA Gastric cancer Phase 2 Phase 2 trial initiation noted June 29, 2017.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
Epacadostat and CRS-207 - SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
ADVM Adverum Biotechnologies Inc.
$3.45
+0.05  1.47%
$149.3 million
43.3 million
1.13
08/09/2017
Tap to view 2 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Phase 1/2 trial to be initiated 4Q 2017.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADXS Advaxis Inc.
$3.82
-0.11  -2.85%
$156.8 million
41.1 million
6.66
10/04/2017
Tap to view 7 drugs
Drug Indication Stage News
ADXS- DUAL Cervical cancer Phase 3 Phase 3 trial to be initiated 1H 2018.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Phase 1b ongoing.
ADXS-PSA and Keytruda Castrate-resistant prostate cancer Phase 1/2 Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Preliminary data due 2018.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Phase 2 initiated June 2016.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Announced Phase 3 first patient dosed - February 6, 2017. Enrollment continues as of August 2017. Data due 2020 or 2021.
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 ongoing.
AERI Aerie Pharmaceuticals Inc.
$65.25
+0.40  0.62%
$2.4 billion
36.3 million
6.94
10/13/2017
Tap to view 2 drugs
Drug Indication Stage News
Rhopressa Glaucoma PDUFA PDUFA date February 28, 2018. Advisory Committee meeting October 13, 2017 voted 9-1 in favor that efficacy outweighs safety risks,
Roclatan - Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data released may 24, 2017 - primary endpoint also hit with NDA filing due 1H 2018. Mercury 3 trial initiation, for EU market, announced September 6, 2017.
AEZS Aeterna Zentaris Inc.
$2.02
+0.01  0.49%
$33.2 million
16.4 million
2.57
07/18/2017
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency PDUFA CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
AFMD Affimed N.V.
$2.13
+0.07  3.66%
$93.4 million
43.9 million
1.19
10/04/2017
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a full data due 2019.
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b update 2H 2017.
AGEN Agenus Inc.
$4.36
-0.12  -2.57%
$434.2 million
99.7 million
8.31
10/14/2017
Tap to view 4 drugs
Drug Indication Stage News
AGEN2034 Solid tumors Phase 1/2 Phase 1/2 initiation announced April 20, 2017.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
Shingrix Shingles PDUFA BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017 at very latest. Given that October 24, 2016 was a Monday it is possible that the filing was made on the Friday (Oct 21, 2016) which would render a PDUFA date as early as October 20, 2017. Advisory Committee Meeting September 13, 2017 voted 11-0 in favor. Shingrix, contains Agenus' adjuvant, QS-21 Stimulon.
AGIO Agios Pharmaceuticals Inc.
$67.17
-1.56  -2.27%
$3.3 billion
48.4 million
15.66
10/10/2017
Tap to view 6 drugs
Drug Indication Stage News
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 initiated 2Q 2017.
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016 with updated data released at EHA June 24, 2017. Pivotal trial to commence 1H 2018.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of April 2017.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Phase 3 NDA filing due by end of 2017.
AGLE Aeglea BioTherapeutics Inc.
$5.03
-0.06  -1.18%
$82.8 million
16.5 million
1.22
10/16/2017
Tap to view 3 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102 Arginase I deficiency Phase 1/2 Phase 1/2 dosing in repeat dose part (Part 2) announced September 6, 2017. Top-line data due 2H 2018.
AEB1102 + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 trial to be initiated 1Q 2018.
AGN Allergan plc
$187.60
-1.67  -0.88%
$62.7 billion
334.3 million
2.28
10/10/2017
Tap to view 24 drugs
Drug Indication Stage News
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2H 2017.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data due 2H 2018.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 2b top-line data due 1H 2018.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Brazikumab Crohn's disease Phase 2b Phase 2b data due 2018.
Brimo DDS Atrophic Age-related macular degeneration (AMD) Phase 2 Phase 2 top-line data due 2H 2017.
Cariprazine Major depressive disorder (MDD) Phase 3 Phase 3 data due 2H 2018.
Cariprazine Schizophrenia/ Negative symptoms – Refusal to file letter issued for sNDA filing - September 22, 2017.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 2 two year data due 2H 2017. Phase 3 trial has been initiated.
Cortisol Analog Dry Eye disease Phase 3 Phase 3 trial to be initiated 2H 2017.
ESMYA (ulipristal acetate) Uterine Fibroids PDUFA Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 to be initiated 2H 2017 with top-line data due 2020.
RORγt agonist Psoriasis Phase 2b Phase 2b trial to be initiated 2H 2017.
Sarecycline Severe acne vulgaris Phase 3 Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
UBROGEPANT Acute (migraine) Phase 3 Phase 3 initiated July 2016. Data due 1H 2018.
AGRX Agile Therapeutics Inc.
$5.05
+0.01  0.20%
$172.7 million
34.2 million
1.59
07/27/2017
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch PDUFA CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted with PDUFA date of December 26, 2017
AGTC Applied Genetic Technologies Corporation
$4.00
+0.10  2.56%
$72.4 million
18.1 million
0.95
09/13/2017
Tap to view 2 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 continues to enroll - September 2017.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
AIMT Aimmune Therapeutics Inc.
$25.66
-0.06  -0.23%
$1.3 billion
50.5 million
15.33
08/09/2017
Tap to view 3 drugs
Drug Indication Stage News
AR101 Peanut Allergy Phase 3 Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 1Q 2018.
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 enrollment has commenced - noted July 5, 2017.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 enrollment to be initiation announced May 11, 2017.
AKAO Achaogen Inc.
$13.80
-0.53  -3.70%
$582.8 million
42.2 million
12.11
09/16/2017
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial to be initiated 1H 2018.
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial Complicated urinary tract infections (cUTI) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
AKBA Akebia Therapeutics Inc.
$17.84
+0.06  0.34%
$841.2 million
47.2 million
5.71
08/09/2017
Tap to view 4 drugs
Drug Indication Stage News
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 data due by the end of 2018.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated 2H 2017 with data due by the end of 2018.
AKCA Akcea Therapeutics Inc.
$18.23
-0.98  -5.10%
$1.2 billion
66.5 million
4.82
09/01/2017
Tap to view 5 drugs
Drug Indication Stage News
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b initiation announced March 30, 2017.
AKCEA-APOCIII-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b trial to be initiated in 2H 2017.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 initiated November 2015
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) NDA Filing Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted. NDA filing announced August 31, 2017.
AKTX Akari Therapeutics Plc
$4.51
+0.19  4.35%
$53.1 million
11.8 million
0.19
10/11/2017
Tap to view 1 drug
Drug Indication Stage News
Coversin Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data released April 24, 2017. Further update due at ASH December 9-12, 2017. Phase 3 program to commence 1Q 2018.
ALBO Albireo Pharma Inc.
$28.19
+0.70  2.55%
$250.4 million
8.9 million
2.41
08/21/2017
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 to be initiated by the end of 2017.
ALDR Alder BioPharmaceuticals Inc.
$11.40
-0.10  -0.87%
$771.9 million
67.7 million
4.10
08/09/2017
Tap to view 3 drugs
Drug Indication Stage News
ALD403 Chronic Migraine Phase 2b Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.
ALD403 - PROMISE 2 Frequent episodic migraine Phase 3 Phase 3 PROMISE 2 enrollment to be completed 2H 2017.
ALDX Aldeyra Therapeutics Inc.
$6.65
-0.10  -1.48%
$100.7 million
15.2 million
0.13
10/10/2017
Tap to view 4 drugs
Drug Indication Stage News
ADX-102 Dry eye syndrome Phase 2a Phase 2a data released September 11, 2017 - noted statistically and clinically significant activity.
ADX-102 Allergic conjunctivitis Phase 2b Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned for 1H 2018.
ADX-102 Noninfectious anterior uveitis Phase 3 Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ADX-102 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 3 trial initial data due 2H 2018.
ALIM Alimera Sciences Inc.
$1.37
-0.01  -0.72%
$94.6 million
69.1 million
4.22
02/26/2017
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
ALKS Alkermes plc
$50.54
-0.02  -0.04%
$7.8 billion
153.7 million
9.17
10/04/2017
Tap to view 9 drugs
Drug Indication Stage News
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-2 Schizophrenia Phase 3 Pivotal trial initiated February 2016. Data due 2018.
ALKS 3831 - ENLIGHTEN-Early Schizophrenia - young adults Phase 3 Phase 3 initiation announced June 8, 2017.
ALKS 5461 Major depressive disorder NDA Filing Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. Rolling NDA filing has commenced - noted August 21, 2017 with submission to be completed by end of 2017.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 8700 Multiple sclerosis (MS) Phase 3 Phase 3 initiation announced March 16, 2017. Completion expected by end of 2017.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filing due 2H 2016
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
ALNY Alnylam Pharmaceuticals Inc.
$114.48
-1.15  -0.99%
$10.5 billion
91.7 million
2.96
09/26/2017
Tap to view 11 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
ALN-CC5 (cemdisiran) Atypical hemolytic-uremic syndrome (aHUS) Phase 1/2 Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
ALN-TTRsc02 ATTR amyloidosis Phase 1 Development plan to be confirmed following APOLLO data release in mid 2017.
Fitusiran Hemophilia A and B Phase 2 Phase 2 trial suspended dosing due to fatal thrombotic event - noted September 7, 2017.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Dosing has yet to be initiated - noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event.
Givosiran Acute hepatic porphyrias Phase 3 Phase 3 trial to be initiated late 2017 with interim analysis data available in mid-2018.
Inclisiran Hypercholesterolemia Phase 3 Phase 3 trial to commence in 2017. Data due by end of 2019.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
ALPN Alpine Immune Sciences Inc.
$11.22
-0.63  -5.32%
$43.9 million
3.9 million
1.13
07/31/2017
Tap to view 1 drug
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALRN Aileron Therapeutics Inc.
$13.65
-0.04  -0.26%
$200.8 million
14.7 million
0.92
08/10/2017
Tap to view 3 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Phase 2a interim data due 1H 2018.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
ALXN Alexion Pharmaceuticals Inc.
$139.21
-1.25  -0.89%
$31.1 billion
223.2 million
3.24
07/27/2017
Tap to view 6 drugs
Drug Indication Stage News
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment to be completed early 2018; expects to initiate a Phase 3 trial in pediatric patients 3Q 2017.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 data due 2Q 2018.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 enrollment to be completed in 2017 with data due 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) PDUFA (sBLA) PDUFA date October 23, 2017.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. No additional studies planned.
AMAG AMAG Pharmaceuticals Inc.
$15.78
-0.28  -1.71%
$556.7 million
35.3 million
8.46
09/16/2017
Tap to view 4 drugs
Drug Indication Stage News
Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 commencement of enrollment announced June 1, 2017.
Feraheme Adults with iron deficiency anemia (IDA) PDUFA PDUFA date February 2, 2018 for sNDA filing.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy PDUFA sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
Rekynda Hypoactive sexual desire disorder (HSDD) Phase 3 NDA filing due early 2018.
AMGN Amgen Inc.
$182.83
-1.29  -0.70%
$133.4 billion
729.7 million
2.96
10/09/2017
Tap to view 19 drugs
Drug Indication Stage News
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 enrolling.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
CNP 520 Alzheimer’s Disease Phase 2/3 Phase 2/3 ongoing. Expected completion 2023.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine PDUFA Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
EVENITY (Romosozumab) Osteoporosis CRL CRL issued July 16, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial initiated June 2015.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Phase 3 Phase 3 trial met primary endpoint. HR 79%.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma PDUFA Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 commencement announced December 1, 2016. Enrollment to continue throughout 2017.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) PDUFA PDUFA date for sBLA filing May 28, 2017.
Repatha Cardiovascular disease PDUFA Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations. PDUFA date under priority review December 2, 2017.
Tezepelumab Asthma Phase 2b Phase 2b data released September 7, 2017 - primary endpoint met.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
XGEVA Multiple Myeloma PDUFA sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
AMPE Ampio Pharmaceuticals Inc.
$1.15
+0.04  3.15%
$78.1 million
68.2 million
16.03
06/22/2017
Tap to view 2 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint - June 2016. Futher trial initiation announced June 22, 2017.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
AMPH Amphastar Pharmaceuticals Inc.
$18.49
+0.04  0.19%
$853.9 million
46.2 million
13.73
02/23/2017
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
AMRN Amarin Corporation plc
$3.44
+0.06  1.77%
$931.5 million
270.8 million
4.41
08/14/2017
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia – Interim analysis announced September 12, 2016 - trial to proceed. Second interim analysis August 14, 2017 also recommended trial to continue. Final data due 2Q or 3Q 2018.
ANAB AnaptysBio Inc.
$64.69
-2.05  -3.07%
$1.3 billion
20.3 million
1.83
10/10/2017
Tap to view 3 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2 Phase 2a positive data released October 10, 2017
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data due 1H 2018.
ANB020 Severe adult peanut allergy Phase 2a Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ANIK Anika Therapeutics Inc.
$59.77
+0.02  0.03%
$876.1 million
14.7 million
17.56
05/25/2017
Tap to view 2 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Additional Phase 3 trial commenced enrollment - May 25 2017. Trial to be completed in 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
ANTH Anthera Pharmaceuticals Inc.
$1.66
+0.04  2.61%
$18.1 million
10.9 million
4.07
09/07/2017
Tap to view 4 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Phase 3 data due end of 2017 or early 2018.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
APHB AmpliPhi Biosciences Corporation
$1.27
+0.04  2.95%
$11.7 million
9.3 million
3.40
01/12/2017
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Chronic rhinosinusitis (CRS) Phase 1 Phase 2 to be initiated 2H 2017.
APRI Apricus Biosciences Inc.
$1.82
+0.00  0.00%
$23.3 million
12.8 million
4.04
08/31/2017
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud's Phenomenon Phase 2b Phase 2b planned - seeking partnership.
Vitaros Erectile dysfunction PDUFA PDUFA date for NDA resubmission February 17, 2018.
AQXP Aquinox Pharmaceuticals Inc.
$12.93
-0.01  -0.08%
$303.4 million
23.5 million
8.82
08/08/2017
Tap to view 4 drugs
Drug Indication Stage News
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 2 Phase 2 planned for 1Q 2018.
ARDM Aradigm Corporation
$5.04
-0.23  -4.36%
$76.2 million
15.1 million
0.46
09/25/2017
Tap to view 2 drugs
Drug Indication Stage News
Linhaliq (Pulmaquin) Non-cystic fibrosis bronchiectasis (non-CF BE). PDUFA priority review PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
Sumavel Migraine Approved Approval granted July 16, 2009.
ARDX Ardelyx Inc.
$5.50
-0.20  -3.51%
$260.9 million
47.4 million
4.58
10/11/2017
Tap to view 5 drugs
Drug Indication Stage News
RDX227675 Hyperkalemia Phase 3 Phase 3 trial initiation announced January 3, 2017.
RDX7675 Hyperkalemia Phase 2 Onset of action trial data due 4Q 2017.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated October 2017.
Tenapanor (T3MPO-1) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
ARGS Argos Therapeutics Inc.
$0.17
+0.00  0.61%
$9.1 million
55 million
0.88
10/04/2017
Tap to view 5 drugs
Drug Indication Stage News
AGS-004 HIV Phase 2 Phase 2 second stage commenced dosing July 2016. Ongoing as of March 2017.
ARGX-113 Pemphigus vulgaris (PV) Phase 2 Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
rocapuldencel-T (AGS-003) Non-Small Cell Lung Cancer Phase 2 Phase 2 initiated 1Q 2016. Ongoing as of November 2016.
rocapuldencel-T (AGS-003) Early stage renal cell carcinoma (RCC) - cancer Phase 2 Phase 2 trial initial data due 2H 2017.
rocapuldencel-T (AGS-003) ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted April 18, 2017 that it intends to continue the trial to 290 events (analysis of overall survival) 1H 2018.
ARGX argenx SE
$23.56
-0.45  -1.85%
$633 million
26.9 million
3.12
10/02/2017
Tap to view 4 drugs
Drug Indication Stage News
ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL) Phase 2 Phase 2 interim data due at ASH 2017 with top-line data due by the end of 2018.
ARGX-110 Acute myeloid leukemia (AML) Phase 1/2 Phase 1/2 interim data due at ASH 2017.
ARGX-113 Immune thrombocytopenia (ITP) Phase 2 Phase 2 data due 2H 2018.
ARGX-113 Myasthenia gravis (MG) Phase 2 Phase 2 data due 1Q 2018.
ARLZ Aralez Pharmaceuticals Inc.
$1.49
+0.00  0.00%
$98.1 million
65.9 million
3.66
02/27/2017
Tap to view 2 drugs
Drug Indication Stage News
VIMOVO Gastric ulcers Approved Approved April 30, 2010.
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
ARNA Arena Pharmaceuticals Inc.
$27.26
-0.05  -0.18%
$1.1 billion
39.2 million
4.67
08/08/2017
Tap to view 8 drugs
Drug Indication Stage News
APD371 Pain associated with Crohn's disease Phase 2 Phase 2 data due year-end 2017 or 1Q 2018.
Etrasimod Primary biliary cholangitis (PBC) Phase 2 Phase 2 to be initiated 2017.
Etrasimod Pyoderma gangrenosum (PG) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Ulcerative colitis Phase 2 Phase 2 data due by end of 2017 or 1Q 2018.
Lorcaserin Obesity Approved Approved June 27, 2012.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.
ARQL ArQule Inc.
$1.10
-0.03  -2.39%
$93.9 million
85.1 million
2.74
08/04/2017
Tap to view 3 drugs
Drug Indication Stage News
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2 Phase 2 data at ASCO June 3, 2017 - ORR 21%. Phase 3 trial planned for 3Q 2017.
ARQ 092 Overgrowth Diseases Phase 1/2 Phase 1/2 trial has commenced enrollment - May 4, 2017.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
ARRY Array BioPharma Inc.
$11.21
-0.13  -1.15%
$1.9 billion
171.8 million
3.32
09/12/2017
Tap to view 7 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated 2017.
ARRY-520 (Filanesib) Refractory Multiple Myeloma Cancer Phase 2 Phase 2 interim data due 2016 but no plans to advance program
Binimetinib - COLUMBUS BRAF mutant melanoma cancer PDUFA Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer Phase 3 PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Data at ESMO September 2017. ORR 41%. Median duration of treatment was 5.6 months.
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
ARWR Arrowhead Pharmaceuticals Inc.
$3.90
-0.10  -2.50%
$291.6 million
74.8 million
2.45
11/30/2016
Tap to view 3 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Announced that development will be discontinued - November 29, 2016.
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Announced that development will be discontinued - November 29, 2016.
ARC-AAT Alpha-1 antitrypsin deficiency (AATD) Phase 2 Announced that development will be discontinued - November 29, 2016.
ASMB Assembly Biosciences Inc.
$31.28
+0.39  1.26%
$541.1 million
17.3 million
4.17
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
ASND Ascendis Pharma A/S
$35.31
-0.52  -1.45%
$1.3 billion
36.4 million
1.85
05/23/2017
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 initiated August 2016. Enrollment to be completed 4Q 2017.
AST Asterias Biotherapeutics Inc. Common Series A
$2.75
-0.05  -1.93%
$137.4 million
50 million
27.02
10/04/2017
Tap to view 3 drugs
Drug Indication Stage News
AST-OPC1 SCiSTAR Cervical spinal cord injury Phase 1/2 Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
AST-VAC1 Acute myeloid leukemia (AML) Phase 2b Phase 2b planned for 2018.
AST-VAC2 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 trial to be initiated 2017.
ATHX Athersys Inc.
$1.95
+0.11  5.98%
$222.1 million
113.9 million
5.54
10/10/2017
Tap to view 2 drugs
Drug Indication Stage News
Multistem Ischemic stroke Phase 3 Phase 2 data released mid April 2015. Endpoints not met. Phase 3 MASTERS-2 trial to be initiated under SPA by the end of 2017.
Multistem Acute myocardial infarction Phase 2 Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
ATNM Actinium Pharmaceuticals Inc. (Delaware)
$0.72
+0.02  2.83%
$57.6 million
80 million
3.01
10/04/2017
Tap to view 2 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 2 Phase 2 to initiated September 2016. Interim analysis due by end of 2017 with top-line data due 1H 2018.
Iomab-B Hematopoietic Stem Cells Transplantation Phase 3 Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
ATNX Athenex Inc.
$17.21
+0.13  0.76%
$982.1 million
57.1 million
5.29
10/04/2017
Tap to view 2 drugs
Drug Indication Stage News
KX-01 Ointment Actinic keratosis Phase 3 Phase 3 patient recruitment announced September 25, 2017.
Oraxol Metastatic breast cancer Phase 3 Phase 3 interim data due 2017.
ATOS Atossa Genetics Inc.
$0.49
-0.01  -2.41%
$5.7 million
11.7 million
0.36
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 enrollment to be completed by August 2017.
ATRA Atara Biotherapeutics Inc.
$14.55
+0.20  1.39%
$444.6 million
30.6 million
25.40
08/08/2017
Tap to view 4 drugs
Drug Indication Stage News
ATA 129 - ALLELE Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT) Phase 3 Phase 3 trial planned for 2H 2017.
ATA 129 - MATCH Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT) Phase 3 Phase 3 trial planned for 2H 2017.
ATA129 and KEYTRUDA Nasopharyngeal carcinoma (NPC) Phase 1/2 Phase 1/2 trial to be initiated 2018.
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
ATRS Antares Pharma Inc.
$2.18
+0.06  2.83%
$341 million
156.4 million
4.30
10/12/2017
Tap to view 4 drugs
Drug Indication Stage News
Anturol Overactive bladder Approved Approved December 8, 2011.
Makena - auto injector Preterm birth PDUFA sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
OTREXUP Rheumatoid arthritis (RA) Approved Approved Oct 14, 2013.
XYOSTED (testosterone enanthate) Testosterone deficiency PDUFA PDUFA date October 20, 2017. Noted October 12, 2017 that the FDA has identified deficiencies with the NDA (i.e. likely CRL coming).
AUPH Aurinia Pharmaceuticals Inc
$6.20
-0.26  -4.10%
$520.2 million
84 million
9.94
05/15/2017
Tap to view 2 drugs
Drug Indication Stage News
Voclosporin - AURION trial Lupus Phase 2 48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURORA Lupus Phase 3 Phase 3 trial initiation announced May 15, 2017.
AVDL Avadel Pharmaceuticals plc
$10.26
+0.09  0.88%
$411.3 million
40.1 million
2.57
02/26/2017
Tap to view 5 drugs
Drug Indication Stage News
Akovaz Hypotension Approved Announced approval May 2 2016
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved Jun 3 2013
Micropump Sodium Oxybate Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy Phase 3 Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
VAZCULEP (phenylephrine hydrochloride) Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia Approved Approved June 30 2014.
AVEO AVEO Pharmaceuticals Inc.
$3.19
+0.02  0.63%
$377.4 million
118.3 million
1.90
10/07/2017
Tap to view 3 drugs
Drug Indication Stage News
Ficlatuzumab EGFR-mutated Non-small cell lung cancer (NSCLC) Phase 2 Announced September 12, 2016 that its Phase 2 trial has been discontinued
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 1Q 2018.
Tivozanib + Opdivo Renal cell cancer (RCC) Phase 1/2 Phase 1/2 initiation of dosing announced March 22, 2017. Phase 2 part of trial initiation announced June 9, 2017.
AVIR Aviragen Therapeutics Inc.
$0.77
+0.05  6.45%
$29.6 million
38.6 million
0.67
08/31/2017
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a data released February 1, 2017 - primary endpoint not met.
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
AVXL Anavex Life Sciences Corp.
$4.89
+0.22  4.71%
$206.2 million
42.2 million
13.29
05/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ANAVEX 2-73 Rett syndrome Phase 2 Phase 2 planned for 2017.
ANAVEX 2-73 Mild to moderate Alzheimer’s disease Phase 2a Phase 2a 12-month data released December 8, 2016. Trial is ongoing. Additional Phase 2/3 trial planned for 2017.
AVXS AveXis Inc.
$100.20
-0.32  -0.32%
$3.2 billion
31.9 million
8.37
09/29/2017
Tap to view 2 drugs
Drug Indication Stage News
AVXS-101 Spinal muscular atrophy (SMA) Phase 1/2 Phase 1/2 trial to be initiated 3Q 2017.
AVXS-101 STR1VE Spinal muscular atrophy (SMA) Type 1 Phase 3 Noted September 29, 2017 plans to initiate Phase 3 trial immediately.
AXON Axovant Sciences Ltd.
$5.73
-0.07  -1.21%
$616.1 million
107.5 million
1.46
10/04/2017
Tap to view 4 drugs
Drug Indication Stage News
Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB) Phase 2b Phase 2b data due 4Q 2017.
Intepirdine - MINDSET Alzheimer's disease Phase 3 Phase 3 data released September 26, 2017 - primary endpoints not met.
Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD) Phase 2 Phase 2 data due 1Q 2018.
Nelotanserin Visual hallucinations in subjects with Lewy body dementia Phase 2 Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due 4Q 2017.
AXSM Axsome Therapeutics Inc.
$5.03
+0.07  1.52%
$118.6 million
23.6 million
5.13
10/07/2017
Tap to view 5 drugs
Drug Indication Stage News
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-05 ADVANCE-1 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 initiation announced July 17, 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AZN Astrazeneca PLC
$34.67
-0.04  -0.12%
$87.8 billion
2.5 billion
3.00
10/18/2017
Tap to view 35 drugs
Drug Indication Stage News
Acalabrutinib Relapsed or Refractory Mantle Cell Lymphoma PDUFA priority review Priority Review announced August 2, 2017. Assume 6-month review rendering a PDUFA date on or around February 1, 2018.
Anifrolumab Lupus Phase 3 Phase 3 data due 2H 2018.
AZD3293 Early Alzheimer's disease Phase 3 Phase 3 data due 2019.
Benralizumab Severe, uncontrolled asthma PDUFA PDUFA 4Q 2017. Exact data not confirmed.
Benralizumab - TERRANOVA COPD Phase 3 Phase 3 data due 2H 2018.
Brilinta (THEMIS) Type 2 Diabetes Phase 3 Phase 3 data due 1Q 2018.
Bydureon Type 2 Diabetes Phase 3 Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Dapa-CKD Chronic Kidney Disease Phase 3